These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
2 files

Catalysis-Enabled Access to Cryptic Geldanamycin Oxides

submitted on 08.01.2020, 16:17 and posted on 09.01.2020, 11:56 by Margaret J. Hilton, Christopher Brackett, Brandon Q. Mercado, Brian S. J. Blagg, Scott Miller
Catalytic, selective modifications of natural products can be a fertile platform for unveiling not only new natural product analogs with altered biological activity, but also for revealing new reactivity and selectivity hierarchies for embedded functional groups in complex environments. Motivated by these intersecting aims, we report site and stereoselective oxidation reactions of geldanamycin facilitated by aspartyl-peptide catalysts. Through the isolation and characterization of four new geldanamycin oxides, we discovered a synergistic effect between lead peptide-based catalysts and geldanamycin, resulting in an unexpected reaction pathway. Curiously, it seems unlikely that our discoveries would not have been possible absent the outer sphere interactions intrinsic to both the catalyst and the natural product. The result is a set of new “meta” catalytic reactions that deliver both unknown and previously incompletely characterized geldanamycin analogs. Enabled by the catalytic, site-selective epoxidation of geldanamycin, biological assays were carried out to document the bioactivities of the new compounds.


Email Address of Submitting Author


Yale University



ORCID For Submitting Author


Declaration of Conflict of Interest

The authors declare no competing financial interest.


Read the published paper

in ACS Central Science